This understanding paves the way for developing diagnostic and prognostic strategies that leverage the selective intracellular localization patterns of TRPV4 and other mechanosensitive ion channels, ultimately guiding clinical decisions for patients with high-risk DCIS and other cancers. This evidence concerns the gene TRPV4 and ductal breast carcinoma in situ.